Verified Nov 2026
Other
·

San Diego, California
·
Since 2007
Neurelis is a biotechnology company headquartered in San Diego, California, founded in 2007. With 200–500 employees and estimated revenue of $250–500 million, the private firm develops therapeutics for neurological conditions, particularly epilepsy and central nervous system disorders. Its flagship product VALTOCO® is an FDA-approved nasal spray formulation of diazepam for acute seizure cluster treatment in patients aged 2 years and older, utilizing proprietary drug delivery technology.
Neurelis, Inc. at a glance
Revenue
$250-500M
Est. band
Employees
200-500
Founded
2007
Headquarters
San Diego, California
Industries
Automotive
Electric Vehicles
Medical
Overview
Neurelis is a biotechnology company headquartered in San Diego, California, founded in 2007. With 200–500 employees and estimated revenue of $250–500 million, the private firm develops therapeutics for neurological conditions, particularly epilepsy and central nervous system disorders. Its flagship product VALTOCO® is an FDA-approved nasal spray formulation of diazepam for acute seizure cluster treatment in patients aged 2 years and older, utilizing proprietary drug delivery technology.
At a glance
Attribute | Detail |
|---|---|
Founded | 2007 |
Headquarters | San Diego, California |
Employees | 200-500 |
Revenue | $250-500M (estimated) |
What Neurelis, Inc. makes
Neurelis develops FDA-approved therapies using proprietary nasal drug delivery technology and intravail formulation systems to address unmet needs in seizure and CNS disorder treatment.
Latest developments
2026-10-15 — News - Neurelis, Inc. (neurelis.com)
2026-09-10 — NEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCE - Neurelis, Inc. (neurelis.com)
2026-06-15 — NEURELIS CEO CRAIG CHAMBLISS NAMED EY US ENTREPRENEUR OF THE YEAR® 2026 PACIFIC SOUTHWEST AWARD WINNER - Neurelis, Inc. (neurelis.com)
2026-01-12 — NEURELIS PROVIDES BUSINESS UPDATE HIGHLIGHTING TRANSFORMATIONAL 2025 RESULTS - Neurelis, Inc. (neurelis.com)
2025-11-10 — NEURELIS TO PARTICIPATE IN SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT - Neurelis, Inc. (neurelis.com)
2025-04-16 — NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 - Neurelis, Inc. (neurelis.com)
Company details
The company is privately held and employs between 200 and 500 staff members. Neurelis, Inc. was founded in 2007, has an estimated 200-500 employees, and is headquartered in San Diego, California.
Frequently asked questions
What does Neurelis, Inc. do?
Neurelis is a biotechnology company headquartered in San Diego, California, founded in 2007. With 200–500 employees and estimated revenue of $250–500 million, the private firm develops therapeutics for neurological conditions, particularly epilepsy and central nervous system disorders. Its flagship product VALTOCO® is an FDA-approved nasal spray formulation of diazepam for acute seizure cluster treatment in patients aged 2 years and older, utilizing proprietary drug delivery technology.
Where is Neurelis, Inc. headquartered?
Neurelis, Inc. is headquartered in San Diego, California (3430 Carmel Mountain Rd, San Diego, California, 92121-1067).
When was Neurelis, Inc. founded?
Neurelis, Inc. was founded in 2007.
How big is Neurelis, Inc.?
Neurelis, Inc. has an estimated 200-500 employees, with revenue in the $250-500M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
